At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CDXS Codexis
Pre-Market Trading 12-23 06:17:47 EST
5.28
+0.16
+3.13%
High5.48
Low5.07
Vol3.25M
Open5.07
D1 Closing5.12
Amplitude8.01%
Mkt Cap429.68M
Tradable Cap308.18M
Total Shares81.38M
T/O17.18M
T/O Rate5.57%
Tradable Shares58.37M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Codexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.